Abstract
Despite the prevalence of psychiatric co-morbidity in chronic hepatitis C (CHC), treatment is under-researched. Patient preferences are likely to affect treatment uptake, adherence, and success. Thus, the acceptability of psychological supports was explored. A postal survey of Australian CHC outpatients of the Royal Adelaide Hospital and online survey of Australians living with CHC was conducted, assessing demographic and disease-related variables, psychosocial characteristics, past experience with psychological support, and psychological support acceptability. The final sample of 156 patients (58 % male) had significantly worse depression, anxiety, stress, and social support than norms. The most acceptable support type was individual psychotherapy (83 %), followed by bibliotherapy (61 %), pharmacotherapy (56 %), online therapy (45 %), and group psychotherapy (37 %). The most prominent predictor of support acceptability was satisfaction with past use. While individual psychotherapy acceptability was encouragingly high, potentially less costly modalities including group psychotherapy or online therapy may be hampered by low acceptability, the reasons for which need to be further explored.
Similar content being viewed by others
References
Australian Bureau of Statistics. (2008). Information paper: An introduction to Socio-Economic Indexes for Areas (SEIFA) 2006.
Bandelow, B., Seidler-Brandler, U., Becker, A., Wedekind, D., & Rüther, E. (2007). Meta-analysis of randomized controlled comparisons of psychopharmacological and psychological treatments for anxiety disorders. World Journal of Biological Psychiatry, 8(3), 175–187.
Bedossa, P., Bioulac-Sage, P., Callard, P., Chevallier, M., Degott, C., Deugniar, Y., et al. (1994). Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. Hepatology, 20, 15–20.
Beltman, M. W., Oude Voshaar, R. C., & Speckens, A. E. (2010). Cognitive-behavioural therapy for depression in people with a somatic disease: Meta-analysis of randomised controlled trials. British Journal of Psychiatry, 197, 11–19.
Castera, L., Constant, A., Henry, C., Champbenoit, P., Bernard, P. H., De Ledinghen, V., et al. (2006). Impact on adherence and sustained virological response of psychiatric side effects during peginterferon and ribavirin therapy for chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 24, 1223–1230.
Chainuvati, S., Khalid, S. K., Kancir, S., Shea, M., Edwards, J., Sernyak, M., et al. (2006). Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders. Journal of Viral Hepatitis, 13, 235–241.
Crepaz, N., Passin, W. F., Herbst, J. H., Rama, S. M., Malow, R. M., Purcell, D. W., et al. (2008). Meta-analysis of cognitive-behavioral interventions on HIV-positive persons’ mental health and immune functioning. Health Psychology, 27, 4–14.
Cuijpers, P., Donker, T., Johansson, R., Mohr, D. C., van Straten, A., & Andersson, G. (2011). Self-guided psychological treatment for depressive symptoms: A meta-analysis. PLoS ONE, 6(6), e21274.
den Boer, P. C. A. M., Wiersma, D., & Van den Bosch, R. J. (2004). Why is self-help neglected in the treatment of emotional disorders? A meta analysis. Psychological Medicine, 34(6), 959–971.
Dillman, D. A. (1991). The design and administration of mail surveys. Annual Review of Sociology, 17, 225–249.
Dwight, M. M., Kowdley, K. V., Russo, J. E., Ciechanowski, P. S., Larson, A. M., & Katon, W. J. (2000). Depression, fatigue, and functional disability in patients with chronic hepatitis C. Journal of Psychosomatic Research, 49, 311–317.
Dwight-Johnson, M., Unutzer, J., Sherbourne, C., Tang, L., & Wells, K. B. (2001). Can quality improvement programs for depression in primary care address patient preferences for treatment? Medical Care, 39(9), 934–944.
El-Serag, H. B., Kunik, M., Richardson, P., & Rabeneck, L. (2002). Psychiatric disorders among veterans with hepatitis C infection. Gastroenterology, 123, 476–482.
Evon, D. M., Simpson, K. M., Esserman, D., Verma, A., Smith, S., & Fried, M. W. (2010). Barriers to accessing care in patients with chronic hepatitis C: The impact of depression. Alimentary Pharmacology and Therapeutics, 32, 1163–1173.
Evon, D. M., Simpson, K., Kixmiller, S., Galanko, J., Dougherty, K., Golin, C., et al. (2011). A randomized controlled trial of an integrated care intervention to increase eligibility for chronic hepatitis C treatment. American Journal of Gastroenterology, 106(10), 1777–1786.
Evon, D. M., Verma, A., Dougherty, K. A., Batey, B., Russo, M., Zacks, S., et al. (2007). High deferral rates and poorer treatment outcomes for HCV patients with psychiatric and substance use comorbidities. Digestive Diseases and Sciences, 52, 3251–3258.
Ghany, M. G., Nelson, D. R., Strader, D. B., Thomas, D. L., & Seeff, L. B. (2011). An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 Practice guideline by the American Association for the Study of Liver Diseases. Hepatology, 54, 1433–1444.
Gidding, H. F., Topp, L., Middleton, M., Robinson, K., Hellard, M., McCaughan, G., et al. (2009). The epidemiology of hepatitis C in Australia: Notifications, treatment uptake and liver transplantations, 1997–2006. Journal of Gastroenterology and Hepatology, 24, 1648–1654.
Gun, S. Y., Titov, N., & Andrews, G. (2011). Acceptability of internet treatment of anxiety and depression. Australasian Psychiatry, 19, 259–264.
Gutteling, J. J., Duivenvoorden, H. J., Busschbach, J. J. V., De Man, R. A., & Darlington, A. S. E. (2010). Psychological determinants of health-related quality of life in patients with chronic liver disease. Psychosomatics, 51, 157–165.
Hauser, P., Khosla, J., Aurora, H., Laurin, J., Kling, M. A., Hill, J., et al. (2002). A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C. Molecular Psychiatry, 7, 942–947.
Holm, S. (1979). A simple sequentially rejective multiple test procedure. Scandinavian Journal of Statistics, 6(2), 65–70.
Jorm, A. F., Christensen, H., Medway, J., Korten, A. E., Jacomb, P. A., & Rodgers, B. (2000). Public belief systems about the helpfulness of interventions for depression: Associations with history of depression and professional help-seeking. Social Psychiatry and Psychiatric Epidemiology, 35, 211–219.
Jorm, A. F., Korten, A. E., Jacomb, P. A., Rodgers, B., Pollitt, P., Christensen, H., et al. (1997). Helpfulness of interventions for mental disorders: Beliefs of health professionals compared with the general public. British Journal of Psychiatry, 171, 233–237.
Kraus, M. R., Schäfer, A., Al-Taie, O., & Scheurlen, M. (2005). Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. Journal of Viral Hepatitis, 12, 96–100.
Kraus, M. R., Schäfer, A., Faller, H., Csef, H., & Scheurlen, M. (2002). Paroxetine for the treatment of interferon-α-induced depression in chronic hepatitis C. Alimentary Pharmacology and Therapeutics, 16, 1091–1099.
Lavanchy, D. (2011). Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection, 17, 107–115.
Leutscher, P. D. C., Lagging, M., Buhl, M. R., Pedersen, C., Norkrans, G., Langeland, N., et al. (2010). Evaluation of depression as a risk factor for treatment failure in chronic hepatitis C. Hepatology, 52, 430–435.
Lewis, C., Pearce, J., & Bisson, J. I. (2012). Efficacy, cost-effectiveness and acceptability of self-help interventions for anxiety disorders: Systematic review. British Journal of Psychiatry, 200(1), 15–21.
Liang, T. J., Rehermann, B., Seeff, L. B., & Hoofnagle, J. H. (2000). Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine, 132, 296–305.
Loftis, J. M., Matthews, A. M., & Hauser, P. (2006). Psychiatric and substance use disorders in individuals with hepatitis C: Epidemiology and management. Drugs, 66, 155–174.
Lovibond, S. H., & Lovibond, P. F. (1995). Manual for the Depression Anxiety Stress Scales (2nd ed.). Sydney, NSW: Psychology Foundation.
Magill, M., & Ray, L. A. (2009). Cognitive-behavioral treatment with adult alcohol and illicit drug users: A meta-analysis of randomized controlled trials. Journal of Studies on Alcohol and Drugs, 70, 516–527.
Martín-Santos, R., Díez-Quevedo, C., Castellví, P., Navinés, R., Miquel, M., Masnou, H., et al. (2008). De novo depression and anxiety disorders and influence on adherence during peginterferon-alpha-2a and ribavirin treatment in patients with hepatitis C. Alimentary Pharmacology and Therapeutics, 27, 257–265.
McDermut, W., Miller, I. W., & Brown, R. A. (2001). The efficacy of group psychotherapy for depression: A meta-analysis and review of the empirical research. Clinical Psychology: Science and Practice, 8, 98–116.
McDonald, J., Jayasuriya, R., Bindley, P., Gonsalvez, C., & Gluseska, S. (2002). Fatigue and psychological disorders in chronic hepatitis C. Journal of Gastroenterology and Hepatology, 17, 171–176.
Morasco, B. J., Huckans, M., Loftis, J. M., Woodhouse, J., Seelye, A., Turk, D. C., et al. (2010). Predictors of pain intensity and pain functioning in patients with the hepatitis C virus. General Hospital Psychiatry, 32, 413–418.
Nelligan, J. A., Loftis, J. M., Matthews, A. M., Zucker, B. L., Linke, A. M., & Hauser, P. (2008). Depression comorbidity and antidepressant use in veterans with chronic hepatitis C: Results from a retrospective chart review. Journal of Clinical Psychiatry, 69, 810–816.
Neri, S., Bertino, G., Petralia, A., Giancarlo, C., Rizzotto, A., Calvagno, G. S., et al. (2010). A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon α and ribavirin. Journal of Clinical Gastroenterology, 44, e210–e217.
Perz, J. F., Armstrong, G. L., Farrington, L. A., Hutin, Y. J. F., & Bell, B. P. (2006). The contributions of hepatitis B virus and hepatitis C virus infections to cirrhosis and primary liver cancer worldwide. Journal of Hepatology, 45, 529–538.
Raison, C. L., Broadwell, S. D., Borisov, A. S., Manatunga, A. K., Capuron, L., Woolwine, B. J., et al. (2005). Depressive symptoms and viral clearance in patients receiving interferon-α and ribavirin for hepatitis C. Brain, Behavior, and Immunity, 19, 23–27.
Raison, C. L., Woolwine, B. J., Demetrashvili, M. F., Borisov, A. S., Weinreib, R., Staab, J. P., et al. (2007). Paroxetine for prevention of depressive symptoms induced by interferon-alpha and ribavirin for hepatitis C. Alimentary Pharmacology and Therapeutics, 25, 1163–1174.
Reavley, N. J., & Jorm, A. F. (2011). Recognition of mental disorders and beliefs about treatment and outcome: Findings from an Australian National Survey of Mental Health Literacy and Stigma. Australian and New Zealand Journal of Psychiatry, 45, 947–956.
Reavley, N. J., & Jorm, A. F. (2012). Public recognition of mental disorders and beliefs about treatment: Changes in Australia over 16 years. British Journal of Psychiatry, 200, 419–425.
Rizzo, M., Creed, F., Goldberg, D., Meader, N., & Pilling, S. (2011). A systematic review of non-pharmacological treatments for depression in people with chronic physical health problems. Journal of Psychosomatic Research, 71, 18–27.
Schaefer, M., Schwaiger, M., Garkisch, A. S., Pich, M., Hinzpeter, A., Uebelhack, R., et al. (2005). Prevention of interferon-alpha associated depression in psychiatric risk patients with chronic hepatitis C. Journal of Hepatology, 42, 793–798.
Sharp, D. M., Power, K. G., & Swanson, V. (2004). A comparison of the efficacy and acceptability of group versus individual cognitive behaviour therapy in the treatment of panic disorder and agoraphobia in primary care. Clinical Psychology and Psychotherapy, 11, 73–82.
Sherbourne, C. D., & Stewart, A. L. (1991). The MOS social support survey. Social Science and Medicine, 32, 705–714.
Stewart, B. J., Mikocka-Walus, A. A., Harley, H., & Andrews, J. M. (2012). Help-seeking and coping with the psychosocial burden of chronic hepatitis C: A qualitative study of patient, hepatologist, and counsellor perspectives. International Journal of Nursing Studies, 49(5), 560–569.
Swift, J. K., & Callahan, J. L. (2009). The impact of client treatment preferences on outcome: A meta-analysis. Journal of Clinical Psychology, 65(4), 368–381.
Swift, J. K., Callahan, J. L., & Vollmer, B. M. (2011). Preferences. Journal of Clinical Psychology, 67(2), 155–165.
The Kirby Institute. (2011). HIV, viral hepatitis and sexually transmissible infections in Australia Annual Surveillance Report 2011. Sydney, NSW: The Kirby Institute, The University of New South Wales.
Thomas, D. L., & Seeff, L. B. (2005). Natural history of hepatitis C. Clinics in Liver Disease, 9, 383–398.
Van Schaik, D. J. F., Klijn, A. F. J., Van Hout, H. P. J., Van Marwijk, H. W. J., Beekman, A. T. F., De Haan, M., et al. (2004). Patients’ preferences in the treatment of depressive disorder in primary care. General Hospital Psychiatry, 26, 184–189.
Vos, T., Corry, J., Haby, M. M., Carter, R., & Andrews, G. (2005). Cost-effectiveness of cognitive-behavioural therapy and drug interventions for major depression. Australian and New Zealand Journal of Psychiatry, 39, 683–692.
Zigmond, A. S., & Snaith, R. P. (1983). The hospital anxiety and depression scale. Acta Psychiatrica Scandinavica, 67, 361–370.
Acknowledgments
We would like to thank Nancy Briggs for providing statistical advice, in addition to Megan Phelps, Anton Colman, and Joanne Morgan for their assistance in data collection. The authors alone are responsible for the content and writing of the paper. This research received no specific funding from the public, commercial, or not-for-profit sectors.
Conflict of interest
The authors report no conflicts of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Stewart, B.J.R., Turnbull, D., Mikocka-Walus, A.A. et al. Acceptability of Psychotherapy, Pharmacotherapy, and Self-Directed Therapies in Australians Living with Chronic Hepatitis C. J Clin Psychol Med Settings 20, 427–439 (2013). https://doi.org/10.1007/s10880-012-9339-7
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10880-012-9339-7